Alpha-5 Selective GABAA Inverse Agonist for Down Syndrome Cognitive Impairment

Solution Overview

Problem

Current treatments for cognitive impairments associated with Down syndrome, such as memory and learning deficits, are inadequate as existing GABAA antagonists often induce seizures and have undesirable side effects, necessitating a non-seizure inducing therapeutic solution.

Innovation Solution

Administration of a compound with inverse agonist functional selectivity for GABAA receptors containing the α5 subunit, specifically α5IA, in combination with a surfactant like polyethoxylated castor oil and dimethyl sulfoxide, to enhance cognitive function without anxiogenic or convulsant effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If GABAA antagonists are administered to treat cognitive impairments in Down syndrome, then learning and memory deficits are improved, but seizures and adverse effects are induced

Engineering Contradiction:

Improvecognitive function improvementVSAvoidseizures and adverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the GABAA receptor system by developing compounds with subtype-selective antagonism. Specifically, the invention targets α5-containing GABAA receptors while sparing other subtypes (α1, α2, α3) that mediate sedative and anxiogenic effects. This segmentation allows cognitive enhancement without the harmful side effects associated with broad-spectrum GABAA antagonism.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by creating antagonists that selectively bind to specific GABAA receptor subtypes (α5-containing receptors) rather than all GABAA receptors. This subtype-specific selectivity localizes the therapeutic effect to cognitive functions while avoiding the adverse effects (seizures, anxiogenesis, sedation) associated with other receptor subtypes.

Inventive Principle:

Principle #3Local quality

2Reliability

If existing GABAA antagonists are used for cognitive enhancement, then memory and learning are improved, but anxiogenic and convulsant effects occur

Engineering Contradiction:

Improvememory and learning improvementVSAvoidanxiogenic and convulsant effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent segments the GABAA receptor system by developing compounds with subtype-selective antagonism. Specifically, the invention targets α5-containing GABAA receptors while sparing other subtypes (α1, α2, α3) that mediate sedative and anxiogenic effects. This segmentation allows cognitive enhancement without the harmful side effects associated with broad-spectrum GABAA antagonism.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by creating antagonists that selectively bind to specific GABAA receptor subtypes (α5-containing receptors) rather than all GABAA receptors. This subtype-specific selectivity localizes the therapeutic effect to cognitive functions while avoiding the adverse effects (seizures, anxiogenesis, sedation) associated with other receptor subtypes.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS9078874B2Composition and method for treating cognitive impairments in down syndrom subjects

Publication Date: 2015.07.14 CENT NAT DE LA RECH SCI (C N R S)

AI summary

Compounds having inverse agonist functional selectivity for GABAA receptors containing the α5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.